VSCA Stock Overview
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4SC AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.98 |
| 52 Week High | €3.46 |
| 52 Week Low | €1.17 |
| Beta | 1.4 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 58.51% |
| 3 Year Change | -65.55% |
| 5 Year Change | -89.51% |
| Change since IPO | -97.30% |
Recent News & Updates
Recent updates
Companies Like 4SC (ETR:VSCA) Could Be Quite Risky
Jan 15
We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth
Aug 04We're Not Very Worried About 4SC's (ETR:VSCA) Cash Burn Rate
Feb 13We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth
Aug 27We Think 4SC (ETR:VSC) Can Afford To Drive Business Growth
Feb 22Our Take On 4SC's (ETR:VSC) CEO Salary
Dec 30
Shareholder Returns
| VSCA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | 58.5% | -21.1% | -0.3% |
Return vs Industry: VSCA exceeded the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: VSCA exceeded the German Market which returned 4.7% over the past year.
Price Volatility
| VSCA volatility | |
|---|---|
| VSCA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VSCA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VSCA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Jason Loveridge | www.4sc.com |
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. The company’s product in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer.
4SC AG Fundamentals Summary
| VSCA fundamental statistics | |
|---|---|
| Market cap | €46.52m |
| Earnings (TTM) | -€14.36m |
| Revenue (TTM) | €436.00k |
106.7x
P/S Ratio-3.2x
P/E RatioIs VSCA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VSCA income statement (TTM) | |
|---|---|
| Revenue | €436.00k |
| Cost of Revenue | €155.00k |
| Gross Profit | €281.00k |
| Other Expenses | €14.64m |
| Earnings | -€14.36m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 10, 2023
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 64.45% |
| Net Profit Margin | -3,293.81% |
| Debt/Equity Ratio | 0% |
How did VSCA perform over the long term?
See historical performance and comparison